190 related articles for article (PubMed ID: 38262152)
1. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis.
Wu J; Li L; Zhu Q; Zhang T; Miao F; Cui Z; Dong G; Tai Z; Chen Z
Biomed Pharmacother; 2024 Feb; 171():116167. PubMed ID: 38262152
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
3. Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice.
Jin W; Huang W; Chen L; Jin M; Wang Q; Gao Z; Jin Z
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544712
[TBL] [Abstract][Full Text] [Related]
4. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
5. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
6. The role of Janus kinase signaling in the pathology of atopic dermatitis.
Guttman-Yassky E; Irvine AD; Brunner PM; Kim BS; Boguniewicz M; Parmentier J; Platt AM; Kabashima K
J Allergy Clin Immunol; 2023 Dec; 152(6):1394-1404. PubMed ID: 37536511
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.
Thoma G; Duthaler RO; Waelchli R; Hauchard A; Bruno S; Strittmatter-Keller U; Orjuela Leon A; Viebrock S; Aichholz R; Beltz K; Grove K; Hoque S; Rudewicz PJ; Zerwes HG
J Med Chem; 2023 Feb; 66(3):2161-2168. PubMed ID: 36657024
[TBL] [Abstract][Full Text] [Related]
10. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
Shih PY; Li CJ; Yong SB
Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT inhibitors for the treatment of atopic dermatitis.
Rodrigues MA; Torres T
J Dermatolog Treat; 2020 Feb; 31(1):33-40. PubMed ID: 30703333
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
14. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
De SK
Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
16. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
17. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
18. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
Fridman JS; Scherle PA; Collins R; Burn T; Neilan CL; Hertel D; Contel N; Haley P; Thomas B; Shi J; Collier P; Rodgers JD; Shepard S; Metcalf B; Hollis G; Newton RC; Yeleswaram S; Friedman SM; Vaddi K
J Invest Dermatol; 2011 Sep; 131(9):1838-44. PubMed ID: 21677670
[TBL] [Abstract][Full Text] [Related]
20. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
